医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and License Agreement

2014年06月14日 AM05:15
このエントリーをはてなブックマークに追加


 

CUPERTINO, Calif.

Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) Osaka, Japan (June 16, 2014) announced today that their Omontys® (peginesatide) product collaboration and license agreement will terminate effective September 10, 2014.

In February 2013, Affymax and Takeda voluntarily recalled all lots of Omontys and suspended promotional activities in the U.S. following postmarketing reports of serious hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal.

Takeda has conducted a detailed investigation of these reactions. The investigation has confirmed no quality or manufacturing issues were present but has not identified a specific root cause for the reactions that were observed.

Based on these findings and related discussions with Takeda, Affymax has elected not to exercise its rights with respect to the Omontys New Drug Application (NDA). Takeda will work with the U.S. Food and Drug Administration to withdraw the Omontys NDA.

The Board of Directors of Affymax is reviewing its strategic options as a result of the termination of the collaboration with Takeda.

This termination does not change the outlook for Takeda’s consolidated results for fiscal 2014.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company based in Cupertino, California. For additional information, please visit www.affymax.com.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

CONTACT

Affymax, Inc.
Lisa Maxson, +1 650-812-8700
or
Takeda
Pharmaceutical Company Limited
Corporate Communications Department,
+81-3-3278-2037

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • New Frontier Health Corporation Announces Receipt of Clarification to Preliminary Non-Binding “Going Private” Proposal
  • 美国项目管理协会发布的《 2021年大趋势》聚焦项目将如何平衡新兴的颠覆力量
  • GNT Pharma’s GedaCure® Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome
  • GNTファーマのGedaCure®が犬の認知障害症候群の治療薬として承認される
  • GNT Pharma的GedaCure®获准用于治疗犬类认知功能障碍综合征